Acadian Seaplants

acadianseaplants.com

Established in 1981, Acadian Seaplants is a family-owned business that revolutionized the seaweed industry in Canada and around the world. Over thirty-five years later, Acadian is the world leader in marine plant products for people, animals and plants. With employees in twelve countries, Acadian is a fully-integrated, biotechnology manufacturer of premium agricultural products for animals and plants, cultivated sea-vegetables and functional ingredients derived from select species of marine plants. The Seaweed Specialists Acadian is an ardent guardian of the marine environment. Decades of research has proven that properly managed, seaweeds are a rapidly renewable marine resource. Pioneer in hand-harvesting technologies that protect the habitat, Acadian is a recognized global leader in the sustainable management of the seaweed resource. Acadian’s products are also eco-efficient, eco-friendly and Acadian is committed to energy efficiency and waste reduction at all stages of manufacturing.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

OLIX PHARMACEUTICALS SUBSIDIARY MCUREX ANNOUNCES MRNA TECHNOLOGY COLLABORATION WITH TOOLGEN FOR RARE EYE DISEASE

OliX | June 20, 2022

news image

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technology. mCureX, specializing in mRNA vaccines and therapeutics, and ToolGen, having expertise in therapeutic gene-editing technologies, have been in active discussions...

Read More

Diagnostics

MACROGENICS USES GENEDATA PROFILER TO IMPROVE IMMUNOTHERAPY DEVELOPMENT

MacroGenics, Genedata | April 20, 2021

news image

Genedata, the leading supplier of enterprise software solutions for biopharmaceutical R&D, revealed today a long-term collaboration agreement with MacroGenics, a biopharmaceutical firm and emerging pioneer in discovering and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics access to Genedata Profiler® as well as consulting services to aid in the platform's accelerated adoption and integration into MacroGenics' R&D infrastructure.
Read More

GSK NABS SPEEDY REVIEW FOR ONE OF ITS TOP PROSPECTS

FierceBiotech | January 21, 2020

news image

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline. After seeming to turn away from oncology R&D under its old CEO Sir Andrew Witty a few years ago, new CEO and R&D head Emma Walmsley and Hal Barron, respectively, have made powering their pipeline out of the slow lane the priority. Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FD...

Read More

Industry Outlook

CULTURE BIOSCIENCES AND CYTIVA TEAM UP TO INNOVATE IN UPSTREAM BIOPROCESSING TO ADVANCE THE DEVELOPMENT AND MANUFACTURING OF NEW THERAPIES

Globenewswire | June 20, 2023

news image

Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities. Together, Cytiva and Culture Biosciences aim to bring to customers new bioprocess solutions that use digitization, in-silico approaches, and virtual monitoring and control of experiments. “Cytiva is excited to work with Culture Biosciences to help customers gain confidence that the process and...

Read More
news image

Medical

OLIX PHARMACEUTICALS SUBSIDIARY MCUREX ANNOUNCES MRNA TECHNOLOGY COLLABORATION WITH TOOLGEN FOR RARE EYE DISEASE

OliX | June 20, 2022

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technology. mCureX, specializing in mRNA vaccines and therapeutics, and ToolGen, having expertise in therapeutic gene-editing technologies, have been in active discussions...

Read More
news image

Diagnostics

MACROGENICS USES GENEDATA PROFILER TO IMPROVE IMMUNOTHERAPY DEVELOPMENT

MacroGenics, Genedata | April 20, 2021

Genedata, the leading supplier of enterprise software solutions for biopharmaceutical R&D, revealed today a long-term collaboration agreement with MacroGenics, a biopharmaceutical firm and emerging pioneer in discovering and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics access to Genedata Profiler® as well as consulting services to aid in the platform's accelerated adoption and integration into MacroGenics' R&D infrastructure.
Read More

news image

GSK NABS SPEEDY REVIEW FOR ONE OF ITS TOP PROSPECTS

FierceBiotech | January 21, 2020

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline. After seeming to turn away from oncology R&D under its old CEO Sir Andrew Witty a few years ago, new CEO and R&D head Emma Walmsley and Hal Barron, respectively, have made powering their pipeline out of the slow lane the priority. Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FD...

Read More
news image

Industry Outlook

CULTURE BIOSCIENCES AND CYTIVA TEAM UP TO INNOVATE IN UPSTREAM BIOPROCESSING TO ADVANCE THE DEVELOPMENT AND MANUFACTURING OF NEW THERAPIES

Globenewswire | June 20, 2023

Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities. Together, Cytiva and Culture Biosciences aim to bring to customers new bioprocess solutions that use digitization, in-silico approaches, and virtual monitoring and control of experiments. “Cytiva is excited to work with Culture Biosciences to help customers gain confidence that the process and...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us